Pacific Biosciences is trading 10.77% down now at $1.16 after its August 5, 2026 earnings release showed $39.0 million in second-quarter revenue, below expectations, and management lowered full-year revenue guidance to $155 million-$165 million.
- Expected cash-flow breakeven was pushed to 2028.
- Investor sentiment was further pressured by a CEO transition and restructuring affecting approximately 40 employees; instrument revenue declined 9.9% year over year.